Human normal immunoglobulin

Key facts

Active substance
Human normal immunoglobulin
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/195/2011
PIP number
Human normal immunoglobulin
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
  • Idiopathic thrombocytopenic purpura (ITP)
  • Neonatal haemolytic disease (ABO - Rh-incompatability)
  • Primary immunodeficiency (PID)
Route(s) of administration
Intravenous use
Contact for public enquiries
LFB Biotechnologies
micardt@lfb.fr
France
Phone: +33 169828842
Fax: +33 169827182
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000167-PIP01-07-M02
Compliance opinion date
15/10/2012
Compliance outcome
positive

Decision

How useful was this page?

Add your rating